Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.
Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.
复制标题
利莫那班对健康人模拟公开演讲引起的焦虑的影响：初步报告。
DOI：
10.1002/hup.2374
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Crippa,JoséA
中科院分区：
文献类型：
--
作者：
Bergamaschi,MateusM;Queiroz,ReginaHC;Chagas,MarcosHN;Linares,IlaMP;Arrais,KátiaC;deOliveira,DanielleCG;Queiroz,MariaE;Nardi,AntonioE;Huestis,MarilynA;Hallak,JaimeEC;Zuardi,AntonioW;Moreira,FabrícioA;Crippa,JoséA
我们调查的假设，利莫那班，大麻素拮抗剂/反向激动剂，将增加健康受试者在模拟公众演讲test.MethodsParticipants的焦虑随机分配到接受口服安慰剂或90毫克利莫那班在一个双盲设计。主观效果采用视觉焦虑情绪量表评定。生理参数，即动脉血压和心率，也monitored.ResultsTwelve参与者接受口服安慰剂和12个接受90毫克利莫那班。与安慰剂相比，利莫那班在预期言语和表现阶段增加了自我报告的焦虑水平。有趣的是，利莫那班没有调节焦虑预应力，并没有与镇静，认知障碍，不适，或血压changes.ConclusionsCannabinoid-1拮抗作用放大了对焦虑刺激的反应，而不干扰预应力阶段。这些数据表明，内源性大麻素系统可能会按需工作，以抵消健康人的焦虑刺激的后果。版权所有© 2013约翰威利父子有限公司.
ObjectiveWe investigated the hypothesis that rimonabant, a cannabinoid antagonist/inverse agonist, would increase anxiety in healthy subjects during a simulation of the public speaking test.MethodsParticipants were randomly allocated to receive oral placebo or 90 mg rimonabant in a double‐blind design. Subjective effects were measured by Visual Analogue Mood Scale. Physiological parameters, namely arterial blood pressure and heart rate, also were monitored.ResultsTwelve participants received oral placebo and 12 received 90 mg rimonabant. Rimonabant increased self‐reported anxiety levels during the anticipatory speech and performance phase compared with placebo. Interestingly, rimonabant did not modulate anxiety prestress and was not associated with sedation, cognitive impairment, discomfort, or blood pressure changes.ConclusionsCannabinoid‐1 antagonism magnifies the responses to an anxiogenic stimulus without interfering with the prestress phase. These data suggest that the endocannabinoid system may work on‐demand to counteract the consequences of anxiogenic stimuli in healthy humans. Copyright © 2013 John Wiley & Sons, Ltd.